Efficacy of nucleotide biocorrector derived from baking yeast of the Saccharomyces cerevis genus in patients with lung tuberculosis

Abstract

There is information on efficacy of immunostimulating agents as a part of therapy of lung tuberculosis. Nucleotide biocorrector is a mixture of nucleotides and nucleosides derived from baking yeast of the Saccharomyces cerevis genus and presenting wide immunomodulating properties. The aim of this study was to investigate efficacy of this agent along with combined chemotherapy in 52 patients with destructive lung tuberculosis. Of them, 27 patients were treated with nucleotide biocorrector (3 g per day orally during 1 month) and conventional chemotherapeutic medication (the study group) and 25 patients (the control group) received equal chemotherapy alone. All the patients were MBT-positive. Immunological examination (CD3+, CD4+, CD8+, СD16+, and CD20+ lymphocytes and their functional activity, anti-MBT-antibodies) was done before and 1 month after starting the treatment; clinical, radiological and laboratory investigations were performed at the same time and additionally in 3 month. Addition of biocorrector to the standard chemotherapy of lung tuberculosis allowed faster normalization of CD3+, CD4+ and CD8+ lymphocytes, enhanced functional activity of T-cell immunity and increased number of CD20+ B-lymphocytes. Moreover, this therapy has facilitated resolution of lung infiltration, eradication of MBT and recovery of tuberculous cavities by the 3rd month of the treatment. Tolerability of biocorrector was good.